ResMed Inc.RMD

Healthcare
Neutral

ASignal's systematic analysis rates RMD as Neutral. ResMed Inc. has a market cap of $29.86B, a P/E of 19.85, a 27.4% net margin, and 10.8% year-over-year revenue growth.

Reflects the latest available analysis · analyzed Jul 9, 2026

The case on RMD

Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.

Bull case
  • Strong operating and gross margins indicating pricing power and cost control
  • Positive free cash flow of $1.45B supporting financial flexibility
  • Low debt-to-equity ratio of 0.13x reflecting strong financial health
  • Return on equity of 25.25% indicating efficient capital use
  • MACD above signal line with expanding histogram suggesting strengthening momentum
  • Price above 20-day and 50-day moving averages confirming uptrend
VS
Bear case
  • PEG ratio of 1.28x suggests potential overvaluation relative to growth
  • High dividend yield of 117% likely erroneous or misreported, requiring data verification
  • Limited Reddit sentiment with only 1 mention indicating low retail interest

Key facts

Sector
Healthcare
Market cap
$29.86B
P/E ratio
19.85
Gross margin
62.2%
Net margin
27.4%
Rev growth YoY
10.8%
Price (Jul 9, 2026)
$205.84

Peers

Clustered with RMD by analysis-profile similarity.

Subscriber-only

See the full verdict on RMD

ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.

How ASignal analyzes RMD

Most investors never get a second opinion, let alone several. ASignal runs RMD past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.

The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.

ResMed Inc. (RMD) Stock Analysis - ASignal rates it Neutral